Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
H. Lundbeck AS's gross profit for the
three
months ended in Mar. 2026 was €779 Mil. H. Lundbeck AS's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was €2,817 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. H. Lundbeck AS's gross profit for the
three
months ended in Mar. 2026 was €779 Mil. H. Lundbeck AS's Revenue for the
three
months ended in Mar. 2026 was €953 Mil. Therefore, H. Lundbeck AS's Gross Margin % for the quarter that ended in Mar. 2026 was 81.74%.
H. Lundbeck AS had a gross margin of 81.74% for the quarter that ended in Mar. 2026 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of H. Lundbeck AS was 82.68%. The lowest was 73.89%. And the median was 77.75%.
H. Lundbeck AS (FRA:LDBA) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
H. Lundbeck AS had a gross margin of 81.74% for the quarter that ended in Mar. 2026 => Durable competitive advantage
H. Lundbeck AS Gross Profit Related Terms
H. Lundbeck AS Gross Profit Historical Data
* Premium members only.
The historical data trend for H. Lundbeck AS's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:LDBA vs ZTS, UTHR, VTRS: Gross Profit Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, H. Lundbeck AS's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
H. Lundbeck AS Gross Profit vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, H. Lundbeck AS's Gross Profit distribution charts can be found below:
* The bar in red indicates where H. Lundbeck AS's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €2,817 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
H. Lundbeck AS (FRA:LDBA) has a Gross Profit of €2,817 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on H. Lundbeck AS and its competitors.
Is H. Lundbeck AS's Gross Profit too high?
H. Lundbeck AS's current Gross Profit is €2,817 Mil. Overall, H. Lundbeck AS has a GF Score™ of 88/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does H. Lundbeck AS's Gross Profit compare to ZTS and UTHR?
H. Lundbeck AS's Gross Profit of €2,817 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Drug Manufacturers company?
A good Gross Profit depends on the Drug Manufacturers industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on H. Lundbeck AS and its competitors. H. Lundbeck AS's current Gross Profit is €2,817 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is H. Lundbeck AS stock overvalued right now?
Based on GuruFocus' analysis, H. Lundbeck AS (FRA:LDBA) is currently considered Modestly Undervalued. The stock's GF Value™ is €6.22, compared to a current price of €5.60 — trading 10% below its estimated fair value. The current Gross Profit is €2,817 Mil. H. Lundbeck AS's overall GF Score™ is 88/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For H. Lundbeck AS (FRA:LDBA), the current Gross Profit is €2,817 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is H. Lundbeck AS (FRA:LDBA) Overvalued in 2026?
Based on GuruFocus' analysis, H. Lundbeck AS stock appears to be undervalued.
The current stock price of €5.60 is trading 10% below its estimated GF Value™ of €6.22.
GuruFocus considers H. Lundbeck AS to be Modestly Undervalued.
Key valuation signals for FRA:LDBA:
Gross Profit: €2,817 Mil
GF Value™: €6.22 vs. price of €5.60 (10% below fair value)
No single metric tells the full story. See the FRA:LDBA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lundbeck is a Denmark-based pharmaceutical firm that focuses on the development and commercialization of central nervous system drugs including antidepressants, antipsychotics, and antiepileptic products. The company's portfolio includes Abilify Maintena and Rexulti for psychosis, Brintellix/Trintellix for depression, Northera for Parkinson's disease symptoms, Sabril and Onfi for seizures, and Vyepti for migraine prevention. Most of the company's sales are derived in North America, followed by Asia and Europe.
88GF Score
Get the complete analysis for FRA:LDBA
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:LDBA has been successfully added to your 
